Form 4 for SABS SAB Biotherapeutics, Inc.
Accepted 2025-04-01 00:00:00 ET · period of report 2025-03-27 · accession 0000950170-25-048551 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-01 | 2025-03-27 | SABS | Kropotova Alexandra | Chief MEDICAL Off | F - Tax | — | -1,179 | 47.2K | -2% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-27 | F | D | 1,179 | — | 47,249 | D | — | — | (F1) Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs"). (F3) Each RSU represents a contingent right to receive one share of Common Stock. (F2) Includes 24,128 shares of Common Stock and 23,121 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended. |